Amedisys, Inc. (AMED)
Chart Events
Performance Outlook
| Previous Close | 122.33 |
| Open | 122.78 |
| Bid | 122.87 x 1000 |
| Ask | 122.81 x 800 |
| Day's Range | 122.17 - 124.85 |
| 52 Week Range | 101.61 - 188.88 |
| Volume | |
| Avg. Volume | 439,124 |
| Market Cap | 3.981B |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | 28.02 |
| EPS (TTM) | 4.38 |
| Earnings Date | Oct 31, 2022 - Nov 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 145.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AMED
Related Research
- Amedisys IncAMED: Lowering target price to $119.00AMEDISYS INC has an Investment Rating of BUY; a target price of $119.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moatlast monthArgus Research
- Simply Wall St.
Returns At Amedisys (NASDAQ:AMED) Appear To Be Weighed Down
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
- GlobeNewswire
Mount Sinai Health System Partners with Contessa to Create Mount Sinai at Home, a Home-Based Care Continuum
Mount Sinai at Home provides home health, hospitalization at home, rehabilitation at home and palliative care at home to patients in the New York metropolitan areaNEW YORK and NASHVILLE, Tenn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Mount Sinai Health System and Contessa, the leading comprehensive home-based care provider, announced the extension of their partnership combining Mount Sinai South Nassau’s home health agency into their existing joint venture. The new combination offers a full continuum
- Zacks
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
